Pharma Stock Sigachi Industries Surges On Credit Rating Reaffirmation From CARE Ratings

The shareholders of Sigachi Industries Limited in the last trading session rose by 2.02 per cent, propelling the counter to close at Rs. 51.49 as compared to a lower Rs. 50.47. The company boasts a market cap of over Rs 1,700 crores and has retained its steep growth curve, with the past five years registering a profit CAGR of 25 per cent.

Affirming their credit ratings further cemented the firm's trust within CARE Ratings Limited adding to the positive pace, further accentuating the operational value of the company. CARE A-; Stable is the rating on long-term bank facilities whilst the combination of long and short term CARE A-; Stable / CARE A2 rating facilities hold. This rating highlights Sigachi's capacity to repay her borrowings as well as her ability to weather adverse market conditions.

Overall, the company performed excellently in FY24 and H1-FY25 and for this reason, Sigachi Industries' performance was highlighted by the rating agency after conducting a thorough review of what was reported. The long-term credit limit has been enhanced to Rs 75.38 crore and short-term credit limit of Rs 51.75 crore to Rs 127.13 crore which are the total amounts for all credit facilities. This re-evaluation therefore indicates to the corporates a profitable aspect and growth opportunities in their finance and more so investors and stakeholders in general.

Furthermore, in an additional development relative to their financial performance, Sigachi continues to grow in the pharmaceutical industry.

Recently, the firm has submitted the CEP (Certificate of Suitability) to EDQM for Propafenone Hydrochloride which is one of the critical APIs for the treatment of cardiac arrhythmias." It establishes the Ekkan group's qualification to the European marketing requirements and also assures them of the approval of EDQM." We expect the potential to reach the signatories' figures of the joints. "The demand for propafenone Hydrochloride is expected to touch nearly 2.1 billion by 2032. We have very good opportunities for growth with Sigachi and its subsidiary Trimax Biosciences ".

Additionally, the company claimed impressive results in their Q2FY25 and H1FY25 financial results. For the second quarter ended Sigachi reported an increase of 38.10 per cent of revenues to reach the sum of 137 crores, while EBITDA increased by 36.91 percent to 29.3 crores and a report of 39.07 percent surge in PAT to reach 21 crores has been achieved in comparison to similar percent a year ago. Whereas in H1FY25, the revenue reported an increase of 26.53 percent making a total of 232.7 crores. There was an increased rate of 33.33 per cent for EBITDA to record a total of 50.40 crore and the PAT recorded an increase of about 29.61 percent to have a total of 33.7 crores.

Sigachi Industries Limited is listed both on NSE and BSE, the pharmaceutical company operates at a global level and has been in the market for more than 33 years. The firm engaged in the development of excipients, C, D vitamin and mineral nutrient blends, APIs and O&M services.

Sigachi has five advanced facilities located in three states: Telangana, Gujarat, and Karnataka. So far, the company has been able to reach clients in 62 countries. In addition to owning a subsidiary in UAE, Sigachi has an established base in Hyderabad as its headquarters in India. Through its US expansion, the company aspires to achieve excellence in the pharmaceutical and food sectors.